Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
97Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $79.95M | $-4.60M | $-0.17 |
| 2024 | $39.01M | $-3.82M | $-0.15 |
| 2023 | $31.64M | $-936.0K | $-0.04 |
| 2022 | $21.25M | $-9.02M | $-0.36 |
| 2021 | $21.83M | $-1.96M | $-0.08 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.16 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.43 vs $0.19beat
- Thu, May 14$0.05 vs $0.10miss
- Thu, Mar 19$0.05 vs $0.12miss
- Thu, Nov 6$-0.07 vs $0.16miss
- Thu, Aug 7$-0.10 vs $-0.01miss
- Tue, May 13$0.07 vs $0.09miss
Estimates and results for ETON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ETONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (6)
- Newsfool.com·1d ago·Negative
Why Eton Pharmaceuticals Is Top of the Class Today Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
View source ↗ - Newsseekingalpha.com·1d ago·Negative
…arnings Like These Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
View source ↗ - Newsseekingalpha.com·1d ago·Positive
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·1d ago·Negative
Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
View source ↗ - Newszacks.com·1d ago·Neutral
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.
View source ↗